A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Phase 2
Active, not recruiting
NCT02711553
| Condition | Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 309 participants |
|---|
| Interventions | Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral |
|---|
| Start date | May 19, 2016 |
|---|
| Completion date | Feb 16, 2018 |
|---|
| Results posted | Feb 26, 2021 |
|---|
Summary
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Progression Free Survival (PFS)
Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months) · Months
| 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 6.47 Months |
|---|
| 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 6.97 Months |
|---|
| Pooled Placebo | 6.64 Months |
|---|
| p-value | 0.4821 |
|---|
| Hazard Ratio (HR) | 1.123 (95% CI 0.904–1.395) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.